|
Metabolomic Analysis Method Adopts NuGel™-HemogloBind™ in Study of Adults with Epilepsy Biotech Support Group reports on a journal article describing the simplicity and efficiency of NuGel™ HemogloBind™, to remove Hemoglobin interference, in a LC-MS metabolomic analysis of plasma in a dietary study of adults with epilepsy. News Release
Metabolomic Analysis Method Adopts NuGel™-HemogloBind™ in Study of Adults with Epilepsy
MONMOUTH
JUNCTION, NJ, February
16, 2023 -- Biotech Support Group reports on a journal article
describing the simplicity and efficiency of NuGel™ HemogloBind™,
to remove Hemoglobin interference, in a LC-MS metabolomic analysis of
plasma in a dietary study of adults with epilepsy.
Leitner,
Dominique F., et al. "Metabolomic,
Proteomic, and Transcriptomic Changes in Adults with Epilepsy on
Modified Atkins Diet." Epilepsia (2023).
High
fat and low carbohydrate diets can reduce seizure frequency in some
treatment-resistant epilepsy patients, including the more flexible
Modified Atkins Diet (MAD). Low carbohydrate diets may shift brain
energy production, particularly impacting neuron and astrocyte linked
metabolism. The study evaluated the effect of short-term MAD on
molecular mechanisms in adult epilepsy patients from surgical brain
tissue and plasma compared to Control participants consuming a
non-modified higher carbohydrate diet. For Plasma Metabolomics, the
article states “Whole blood was thawed on ice and processed to
remove hemoglobin by NuGel-HemogloBind according to manufacturer
protocol…samples were analyzed with the hybrid LCMS assay after
scaling metabolite extraction to 100ul/sample.”. The article
concludes that Short-term MAD was associated with metabolic
differences in plasma and resected epilepsy brain tissue when
compared to Control participants; there were 13 increased metabolites
in plasma that included 4.10-fold increased ketone body
3-hydroxybutyric acid, decreased palmitic acid in cortex, and 11
decreased metabolites in hippocampus, that had top associations with
mitochondrial functions. “Here is another example of the versatility of NuGel™ HemogloBind™, as it is used here to clear interference in LC-MS metabolomic analysis. While NuGel™ HemogloBind™ is intended specifically for Hemoglobin removal, a related product - NuGel™ BindPro™, also can fulfill the function of a general aqueous protein crash reagent for metabolomic analysis.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.
Click here for more information on NuGel™ HemogloBind™ Click here for more information on all of our Hemoglobin Removal products
Click
here for more information on NuGel™ BindPro™
About Biotech Support Group LLC
Converging with technological disruptions forthcoming in healthcare, Biotech Support Group continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, For more information, go to http://www.biotechsupportgroup.com.
For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com |
- About
- Products
- Hemoglobin Removal Kits
- Lipid Removal & Clarification
- Urine Protein & Low Abundance Enrichment
- Class Specific Enrichment
- Sample Prep Mass Spectrometry
- Functional & Chemical Proteomics
- Genomic Sample Prep
- Accessories
- Technical Resources
- References
- Publications & Reports
- FAQs
- Case Studies
- Ectodomain Shedding and Enrichment of the Soluble Membrane Proteome
- Methods to selectively deplete or purify Hemoglobin from Dried Blood Spots (DBS)
- The Utility of HemoVoid™ is Demonstrated in 3 Proteomic Investigations Identifying Potential Disease Specific Biomarkers
- The 4 common features of our sample prep products, known as the BSG Advantage, are highlighted in a selection of journal references.
- AlbuVoid™ Workflows Advance Cell Secretome Proteomics
- Lipid Removal for Phenotypic Cell Response in Cancer Research
- The Influence of Sample Prep Bias on LC-MS Targeted Peptide Quantification in Serum Proteomics
- Re-imagining proteomics for developing precision medicine biomarkers of the innate immune response in SARS-CoV-2
- Patent Application Describes New Proteomic Methods to Monitor Protease Inhibitor Function During Covid-19 Infections
- Efficient Hemoglobin Removal Advances Red Cell Proteomics Offering Many New Insights Into Inflammation and Infectious Disease
- The Potential for New Blood Biomarkers in the Management of COVID-19 Disease
- Establishing the Utility of HemoVoid™ and HemogloBind™ as Enrichment Tools for Proteomic Analysis of Red Cells and Whole Blood in Parkinson’s Disease
- Species Diversity Supported By BSG Products
- Poster Report Describes Loss of Functional Serpin Activity In Cancer Patient Blood
- AlbuVoid™️ PLUS & AlbuSorb™️ PLUS Evaluating Different Windows of Observation Solves The Many Challenges of Serum Proteomics
- Tackling the Challenges of Serum Proteomics
- Lipid Removal Sample Prep for Cell Response Applications
- Sample Prep for Proteomic Analysis of Saliva
- Biotech Support Group Featured in Book, "Functional Proteomics – Methods and Protocols"
- Sample Prep Liquid Biopsy Products Suitable for Proteomic Profiling of a Variety of Body Fluid Sample Types
- Albumin and High Abundance Depletion
- Using HemogloBind™ as a Hemoglobin Binding Reagent
- Diverse technologies available for researchers to selectively bind or enrich exosomes and extracellular vesicles.
- Stroma Liquid Biopsy™ Biomarkers Profile Pan-Cancer Dysregulation of the Serum Proteome
- Diverse Depletion and Enrichment Technologies Enhance Simplicity and Efficiency of Obtaining Quality Proteomic Information
- Use On-Bead Digestion to Improve Time Required for Serum Digestion
- Using AlbuVoid™ as a Serum Protein Enrichment Kit in Functional Proteomics
- Using Cleanascite™ as a Lipid Absorption and Clarification Reagent
- Using HemoVoid to Remove Hemoglobin Before Analysis
- Contact
- Liquid Biopsy
